Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Entropy NeurodynamicsTYPTF Equity-to-Asset is 0.88 as of Dec. 2025, which is at its 10-year median of 0.88. The stock has 5 warning signs investors should review. Among 1,417 Biotechnology companies, Entropy Neurodynamics ranks better than 79.25% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Entropy Neurodynamics Equity-to-Asset Related Terms
Entropy Neurodynamics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Entropy Neurodynamics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TYPTF vs VRTX, REGN, ALNY: Equity-to-Asset Comparison
For the Biotechnology subindustry, Entropy Neurodynamics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entropy Neurodynamics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entropy Neurodynamics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Entropy Neurodynamics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Entropy Neurodynamics's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entropy Neurodynamics (TYPTF) has a Equity-to-Asset of 0.88 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Entropy Neurodynamics and its competitors. This is near median its historical median of 0.88. Over the past decade, Entropy Neurodynamics' Equity-to-Asset has ranged from 0.62 to 0.99. According to the industry distribution chart, Entropy Neurodynamics ranks #294 out of 1417 companies in the Biotechnology industry, placing it in the top 20.7%.
Is Entropy Neurodynamics' Equity-to-Asset too high?
Entropy Neurodynamics' current Equity-to-Asset of 0.88 is near median its 10-year median of 0.88. Over the past 10 years, this metric has ranged from a low of 0.62 to a high of 0.99. The Biotechnology industry median Equity-to-Asset is 0.68. Entropy Neurodynamics' value of 0.88 is 29.4% above this industry median. Based on the distribution chart, Entropy Neurodynamics ranks #294 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Entropy Neurodynamics' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Entropy Neurodynamics ranks #294 out of 1417 companies for Equity-to-Asset. This places Entropy Neurodynamics in the top 21% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Entropy Neurodynamics' value of 0.88 is 29.4% above this benchmark. Historically, Entropy Neurodynamics' own Equity-to-Asset has ranged from 0.62 to 0.99 over the past decade. While the company's 10-year median is 0.88 vs. the industry median of 0.68, Entropy Neurodynamics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Entropy Neurodynamics's current Equity-to-Asset of 0.88 is 29.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Entropy Neurodynamics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entropy Neurodynamics's current Equity-to-Asset is 0.88, which is near median its own 10-year median of 0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (TYPTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 25% above its estimated fair value. The current Equity-to-Asset is 0.88, which is near median its 10-year median of 0.88 and 29.4% above the Biotechnology industry median of 0.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Entropy Neurodynamics (TYPTF), the current Equity-to-Asset is 0.88 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TYPTF has been successfully added to your 
